02 May 2024 --- The British Dietetic Association (BDA) and the British Nutrition Foundation (BNF) recommend that GLP-1 and GIP receptor agonist medication are offered alongside a reduced-calorie diet and increased physical activity for adults with obesity or type 2 diabetes and call for equal access to the medicines. They urge the food environment to change and “make it easier to eat healthier diets,” as drugs are not the solution to growing obesity rates. In a joint statement, the organizations support using glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) receptor agonist medications as long as they are prescribed safely and appropriately.
